{
  "id": "adv_mhgap#referral_ecd0e2e1",
  "content": "and meta-analysis of medications for stimulant\nsynthesis No. 187. Rockville (MD): Agency for\nuse disorders in patients with co-occurring\nHealthcare Research and Quality; 2020 (https://\nopioid use disorders. Drug Alcohol Depend.\nwww.ncbi.nlm.nih.gov/books/NBK558205/).\n2020;216:108193 (https://doi.org/10.1016/j.\n143. World drug report 2022. Vienna: United Nations drugalcdep.2020.108193).\nOffice on Drugs and Crime; 2022 (https://www.\n151. Buchholz J, Saxon AJ. Medications to treat\nunodc.org/unodc/data-and-analysis/world-drug-\ncocaine use disorders: current options. Curr\nreport-2022.html).\nOpin Psychiatry. 2019;32(4):275–81 (https://doi.\n144. Cannabis use disorders – level 4 cause. Seattle org/10.1097/YCO.0000000000000518).\n(WA): The Institute for Health Metrics and\n152. Chan B, Kondo K, Freeman M, Ayers C,\nEvaluation; 2019 (https://www.healthdata.org/\nMontgomery J, Kansagara D. Pharmacotherapy\nresults/gbd_summaries/2019/cannabis-use-\nfor cocaine use disorder – a systematic\ndisorders-level-4-cause, accessed 20 October\nreview and meta-analysis. J Gen Intern Med.\n2023).\n2019;34(12):2858–73 (https://doi.org/10.1007/\n145. Degenhardt L, Ferrari AJ, Calabria B, Hall s11606-019-05074-8).\nWD, Norman RE, McGrath J et al. The global\n153. Fluyau D, Revadigar N, Pierre CG. Systematic\nepidemiology and contribution of cannabis\nreview and meta-analysis: treatment of substance\nuse and dependence to the global burden of\nuse disorder in attention deficit hyperactivity\ndisease: results from the GBD 2010 study. PLoS\ndisorder. Am J Addict. 2021;30(2):110–21 (https://\nOne. 2013;8(10):e76635 (https://doi.org/10.1371/\ndoi.org/10.1111/ajad.13133).\njournal.pone.0076635).\n124\nReferences\n154. Siefried KJ, Acheson LS, Lintzeris N, Ezard N. 162. Sancho M, De Gracia M, Rodríguez RC, Mallorquí-",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Referral and meta-analysis of medications for stimulant\nsynthesis No. 187. Rockville (MD): Agency for\nuse disorders in patients with co-occurring\nHealthcare Research and Quality; 2020 (https://\nopioid use disorders. Drug Alcohol Depend.\nwww.ncbi.nlm.nih.gov/books/NBK558205/).\n2020;216:108193 (https://doi.org/10.1016/j.\n143. World drug report 2022. Vienna: United Nations drugalcdep.2020.108193).\nOffice on Drugs and Crime; 2022 (https://www.\n151. Buchholz J, Saxon AJ. Medications to treat\nunodc.org/unodc/data-and-analysis/world-drug-\ncocaine use disorders: current options. Curr\nreport-2022.html).\nOpin Psychiatry. 2019;32(4):275–81 (https://doi.\n144. Cannabis use disorders – level 4 cause. Seattle org/10.1097/YCO.0000000000000518).\n(WA): The Institute for Health Metrics and\n152. Chan B, Kondo K, Freeman M, Ayers C,\nEvaluation; 2019 (https://www.healthdata.org/\nMontgomery J, Kansagara D. Pharmacotherapy\nresults/gbd_summaries/2019/cannabis-use-\nfor cocaine use disorder – a systematic\ndisorders-level-4-cause, accessed 20 October\nreview and meta-analysis. J Gen Intern Med.\n2023).\n2019;34(12):2858–73 (https://doi.org/10.1007/\n145. Degenhardt L, Ferrari AJ, Calabria B, Hall s11606-019-05074-8).\nWD, Norman RE, McGrath J et al. The global\n153. Fluyau D, Revadigar N, Pierre CG. Systematic\nepidemiology and contribution of cannabis\nreview and meta-analysis: treatment of substance\nuse and dependence to the global burden of\nuse disorder in attention deficit hyperactivity\ndisease: results from the GBD 2010 study. PLoS\ndisorder. Am J Addict. 2021;30(2):110–21 (https://\nOne. 2013;8(10):e76635 (https://doi.org/10.1371/\ndoi.org/10.1111/ajad.13133).\njournal.pone.0076635).\n124\nReferences\n154. Siefried KJ, Acheson LS, Lintzeris N, Ezard N. 162. Sancho M, De Gracia M, Rodríguez RC, Mallorquí- And meta-analysis of medications for stimulant\nsynthesis no. 187."
}